Abbott (NYSE:ABT) said today that it won CE Mark approval in the European Union for its next-generation drug-eluting stent, the Xience Sierra.
The everolimus-eluting coronary stent is designed to allow cardiologists to treat the complex lesions that make up roughly 70% of cases, the Chicago-area healthcare giant said. If offers a thinner profile, increased flexibility, longer lengths and smaller diameters than previous stents.
Get the full story at our sister site, Drug Delivery Business News.